BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 14601087)

  • 1. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma.
    Urba SG; Orringer MB; Ianettonni M; Hayman JA; Satoru H
    Cancer; 2003 Nov; 98(10):2177-83. PubMed ID: 14601087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
    Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: preliminary results of a Minnie Pearl Cancer Research Network phase II trial.
    Meluch AA; Hainsworth JD; Gray JR; Thomas M; Whitworth PL; Davis JL; Greco FA
    Cancer J Sci Am; 1999; 5(2):84-91. PubMed ID: 10198730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy.
    Brenner B; Ilson DH; Minsky BD; Bains MS; Tong W; Gonen M; Kelsen DP
    J Clin Oncol; 2004 Jan; 22(1):45-52. PubMed ID: 14701767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer.
    Kim DW; Blanke CD; Wu H; Shyr Y; Berlin J; Beauchamp RD; Chakravarthy B
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):397-404. PubMed ID: 17097833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report.
    Henry LR; Goldberg M; Scott W; Konski A; Meropol NJ; Freedman G; Weiner LM; Watts P; Beard M; McLaughlin S; Cheng JD
    Ann Surg Oncol; 2006 Feb; 13(2):214-20. PubMed ID: 16418887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective dose escalation of chemoradiotherapy for esophageal cancer: role of treatment intensification.
    Seung SK; Smith JW; Molendyk J; Bader SB; Phillips M; Regan J; Louie J; Soo E; Seligman M; Ruzich J; Skokan L; Ross HJ
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):13-9. PubMed ID: 15726517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
    Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
    J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
    Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer.
    Roof KS; Coen J; Lynch TJ; Wright C; Fidias P; Willett CG; Choi NC
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1120-8. PubMed ID: 16730135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
    Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
    Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
    Ishida K; Ando N; Yamamoto S; Ide H; Shinoda M
    Jpn J Clin Oncol; 2004 Oct; 34(10):615-9. PubMed ID: 15591460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Phase II study of paclitaxel and cisplatin for advanced squamous-cell carcinoma of esophagus].
    Huang J; Cai RG; Meng PJ; Zhang MJ; Cui CX; Yang L; Chu DT; Sun Y; Wang JW
    Zhonghua Zhong Liu Za Zhi; 2004 Dec; 26(12):753-5. PubMed ID: 15733398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
    Hitt R; López-Pousa A; Martínez-Trufero J; Escrig V; Carles J; Rizo A; Isla D; Vega ME; Martí JL; Lobo F; Pastor P; Valentí V; Belón J; Sánchez MA; Chaib C; Pallarés C; Antón A; Cervantes A; Paz-Ares L; Cortés-Funes H
    J Clin Oncol; 2005 Dec; 23(34):8636-45. PubMed ID: 16275937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoradiotherapy for T3 and T4 squamous cell carcinoma of the esophagus using low-dose FP and radiation: a preliminary report.
    Fujiwara Y; Kamikonya N; Inoue T; Koishi K; Yoshikawa R; Nakao K; Yagyu R; Nishiwaki M; Fujiwara M; Kojima S; Nakagawa K; Yamamura T
    Oncol Rep; 2005 Nov; 14(5):1177-82. PubMed ID: 16211282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.
    Sonett JR; Suntharalingam M; Edelman MJ; Patel AB; Gamliel Z; Doyle A; Hausner P; Krasna M
    Ann Thorac Surg; 2004 Oct; 78(4):1200-5; discussion 1206. PubMed ID: 15464470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma.
    Papadimitrakopoulou VA; Ginsberg LE; Garden AS; Kies MS; Glisson BS; Diaz EM; Clayman G; Morrison WH; Liu DD; Blumenschein G; Lippman SM; Schommer D; Gillenwater A; Goepfert H; Hong WK
    Cancer; 2003 Nov; 98(10):2214-23. PubMed ID: 14601092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma.
    Chua DT; Sham JS; Au GK
    Head Neck; 2004 Feb; 26(2):118-26. PubMed ID: 14762880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.